Athlotype gives sports teams and their physicians a complete genetic picture of how each athlete's body processes drugs, recovers from injury, and responds to treatment — before a single pill is prescribed.
Sports medicine still runs on population averages. The same NSAID dose. The same post-surgical opioid protocol. The same caffeine recommendation — for every player on the roster, regardless of biology.
Every athlete metabolizes medications differently due to genetic variation. A player with the CYP2C9 poor metabolizer variant accumulates NSAID levels 3–5× higher than average on a standard dose, compounding to potential long-term kidney damage. A CYP2D6 ultra-rapid metabolizer given standard codeine after ACL surgery converts it to dangerous morphine levels. These are not edge cases — ~30% of athletes carry at least one clinically significant pharmacogenomic variant.
"Two athletes on the same ibuprofen dose can have blood levels 5× apart due to a single genetic variant in CYP2C9. One is under-treated. The other is quietly damaging their kidneys."
Standard doses were designed for a fictional average patient. Genetic variation causes people to metabolize the same drug at rates that differ by 5–60× between individuals.
Pharmacogenomics has FDA recognition and CPIC clinical guidelines covering 100+ gene-drug pairs. None of this is being applied in professional sports medicine.
Platforms like InsightRX use blood data to adjust doses after a drug is started. Athlotype tells you the right dose before the first pill — then refines continuously.
Existing tools give data to teams, not athletes. Athlotype is built differently: athletes own their genomic data and control exactly what's shared, with whom, and for how long.
A single saliva sample powers a lifetime of more precise medical decisions. No repeat testing. No guessing.
At onboarding, the athlete provides a saliva sample. Athlotype coordinates with a CLIA-certified lab to analyze 35 pharmacogenomically relevant genes using a targeted panel — primers designed specifically for those loci. No full genome is sequenced or stored. Results return within 48–72 hours and are stored permanently in the platform. This happens once per athlete, ever.
When the team physician makes a treatment decision — post-game NSAID protocol, pre-surgery opioid planning, recovery intervention, supplement protocol — Athlotype surfaces the relevant genomic context and a plain-language recommendation grounded in CPIC clinical guidelines and the athlete's specific variants.
As athletes accumulate drug exposures and outcome data, Athlotype learns which interventions work for which genomic profiles. Every athlete sequenced makes recommendations smarter for everyone. This is the data flywheel that makes Athlotype more valuable over time.
Athlotype doesn't look at everything — it looks at exactly the right things. Every gene in the panel has a specific clinical application in sports medicine. We do not screen for injury predisposition, disease risk, or anything that could affect an athlete's career or insurability. That's a deliberate design choice, not a limitation.
The panel covers only pharmacogenomic and physiologically actionable variants. What's analyzed, what's excluded, and why — explained to every athlete in plain language before they consent.
How the body processes NSAIDs, opioids, caffeine, cardiac medications, antidepressants. The core pharmacogenomic layer.
How strongly the body generates and resolves inflammation after exercise or injury. Governs NSAID response and recovery protocols.
Mitochondrial efficiency, lactate clearance, antioxidant capacity. How quickly the body genuinely recovers between intense efforts.
Whether caffeine is genuinely ergogenic for this athlete, at what dose and time — or whether it disrupts sleep with no performance benefit.
Pain sensitivity, stress resilience, cognitive performance under pressure. Critical for opioid dosing and return-to-play decisions after concussion.
VO₂max ceiling, muscle fiber architecture, cardiovascular adaptation, altitude training response. Informs training load design.
Vitamin D receptor function, iron metabolism, lactose tolerance, folate processing. Why the same supplement stack produces different results for different athletes.
Injury predisposition genes, disease risk variants, longevity markers, or anything that could affect contract negotiations or insurability. Athletes have a right not to know this — and we agree.
Athlotype starts where the need is clearest, the willingness to pay is highest, and the sales cycle is fastest. Professional sports teams can move in weeks. Hospitals take years.
Every game matters. High injury rate means constant drug exposure. Pre-season physicals create a natural onboarding moment for sequencing all 53 roster players at once.
82 games plus playoffs, heavy travel, constant NSAID and recovery drug use across a 7-month grind. High player salaries make the ROI conversation trivial. Sophisticated analytics culture already exists.
162-game season across 6 months. Pain management during a marathon season is the biggest unmet need. Chronic NSAID use in pitching arms creates real kidney risk without genomic guidance.
Global expansion opportunity. European clubs invest heavily in sports science. Player longevity is a primary club asset.
Extreme weight cutting involves medications with high genomic variability. Fighters are motivated and regulatory bodies want tools that improve medical safety.
National governing bodies have centralized decision-making. A single NGB deal covers an entire sport and signals credibility globally.
NCAA programs represent a uniquely compelling market. 4-year roster turnover creates recurring sequencing revenue built into the natural rhythm of each sport. 350 Division I basketball programs at $40K each represents $14M in addressable ARR — before football.
Athlotype is built on a simple principle: the athlete is not a data source. They are a person who owns their most personal information and decides what happens with it.
Saying no requires zero action. No form, no explanation, no conversation. An athlete who doesn't participate simply doesn't open the app. Their medical care is identical to what it was before Athlotype existed. Nothing changes. No pressure.
When you change teams, your genomic profile belongs to you — not your former team. You can authorize your new physician to access it, or keep it private. If you revoke consent, your data is deleted from Athlotype's systems. Not archived. Deleted.
Your genomic data is accessible only to the team physician you designate, for medical care decisions only. The GM, coach, or agent cannot see it. This isn't just a policy — it's technically enforced in the platform architecture.
Not a 40-page terms of service. A plain-language explanation of every gene being analyzed, why it matters, and what it means for your medical care — in a way that actually makes sense.
Sequenced at your first team? That profile is yours forever. Authorize your next team's physician to access it — or don't. One saliva sample, one lifetime of portable genomic health data.
Genes like COL1A1 and COL5A1 affect connective tissue structure. We don't analyze them. An athlete has a right not to know information that could affect their career.
The team pays the subscription. That doesn't buy them your data. The commercial relationship and the medical relationship are completely separate, and that separation is enforced in code.
De-identified data may eventually be used for research — but only with a separate, specific opt-in. Participation in Athlotype does not automatically include research consent.
Revocation is one button. Immediate. Triggers data deletion. No retention period, no grace window. Your choice is final and irreversible on our end.
No full genome. No disease risk. No ancestry. No anything beyond what has direct clinical utility for your medical care.
Every consenting athlete generates a labeled training example: genome → drug → dose → outcome. Linked to real clinical outcomes in elite athletes. This dataset doesn't exist anywhere at scale today.
After 10,000 athletes, Athlotype's model is significantly better than anything a new entrant can build from scratch. The switching cost compounds: teams that have used the platform for 3 years have richer profiles than any alternative can offer.
Athletes carry their genomic profile across teams. A player sequenced at their first team arrives at their next team already in the system. Every trade and free agency signing grows the network.
One flat annual fee per team. Covers the full platform — onboarding, genomic profiling, physician decision support, and ongoing recommendations. No per-query charges, no hidden costs.
We are building our clinical advisory board. If you are a sports medicine physician or pharmacogenomics researcher interested in shaping the future of precision sports medicine, we want to hear from you.
Athlotype is in early development. We're partnering with forward-thinking sports medicine physicians and teams who want to build this together.